AR013152A1 - Derivados de 2-alquilheterodihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n. - Google Patents

Derivados de 2-alquilheterodihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n.

Info

Publication number
AR013152A1
AR013152A1 ARP980103174A ARP980103174A AR013152A1 AR 013152 A1 AR013152 A1 AR 013152A1 AR P980103174 A ARP980103174 A AR P980103174A AR P980103174 A ARP980103174 A AR P980103174A AR 013152 A1 AR013152 A1 AR 013152A1
Authority
AR
Argentina
Prior art keywords
alkyl
derivatives
alkoxy
halogen
optionally substituted
Prior art date
Application number
ARP980103174A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR013152A1 publication Critical patent/AR013152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de 2-alquilheterodihidropirimidina, que comprende la formula I que se incluye su forma tautomérica 3,4-dihidropirimidina en donde: R1representa SR6, NR6R7 o OR6; R2 representa alquilo C1 a 6 o alquilo C2 a 6 insaturado, incluyendo optativamente O o S, y que es sustituido por fenilo o unanillo heteroarilo monocíclico, anillo aromático que es optativamente sustituído por uno o más sustituyentes independientemente seleccionados entrehalogeno, alquilo C1 a 6 o alcoxi C1 a6; R3 representa un anillo aromático monocíclico o bicíclico optativamente incorporado un heteroátomo seleccionadoentre N, O o S, optativamente sustituido por uno o más sustituyentes seleccionado independientemente entre halogeno, alquilo C1-6, alcoxi C1-6,ciano, trifluorometilo, amino, hidroxi, nitro o carbometoxi; R4 y R5 representa piperidinilo, morfolinilo, 3,4-deshidropiperidinilo, tiomorfolinilo,pirrolidinilo, N-metilpiperidinio, piperazinilo adicionalmente sustituido en N-4 por alquilo C1 a 6; R6 y R7 representan independientemente alquilo C1 a 6 oCicloalqiulo C3 a 6, o bencilo, optativamente sustituido en el anillo fenilo por alquilo C1 a 6 alcoxi, alcoxi C1 a 6 o halogeno; X representa O, S o NR8;R8representa hidrogeno o alquilo C1 a 6; y n representa un entero de 2 a 4; y sus isomeros opticos y racematos y sus sales farmacéuticamente aceptables;procesos para su preparacion composiciones que los contienen y su uso como antagonista de los canales de calcio neuronales tipo N utiles en el tratamientode la isquemia cerebrovascular y el dolor. Para la fabricacion de un medicamento util.
ARP980103174A 1997-07-02 1998-06-30 Derivados de 2-alquilheterodihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n. AR013152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702563A SE9702563D0 (sv) 1997-07-02 1997-07-02 Compounds

Publications (1)

Publication Number Publication Date
AR013152A1 true AR013152A1 (es) 2000-12-13

Family

ID=20407619

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103174A AR013152A1 (es) 1997-07-02 1998-06-30 Derivados de 2-alquilheterodihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n.

Country Status (9)

Country Link
US (1) US6057332A (es)
EP (1) EP0994859A1 (es)
JP (1) JP2002507988A (es)
AR (1) AR013152A1 (es)
AU (1) AU8249898A (es)
CA (1) CA2294882A1 (es)
SE (1) SE9702563D0 (es)
WO (1) WO1999001437A1 (es)
ZA (1) ZA985329B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078730A1 (fr) * 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Nouveaux derives dihydropyrimidiniques
WO2003066040A1 (fr) * 2002-02-05 2003-08-14 Ajinomoto Co.,Inc. Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
AU2003288443B2 (en) * 2002-12-16 2007-10-25 Astrazeneka Uk Limited Process for the preparation of pyrimidine compounds
WO2005015159A2 (en) * 2003-08-08 2005-02-17 The Regents Of The University Of California. Methods for modulating a drug-related effect or behavior
JP6250561B2 (ja) 2012-02-08 2017-12-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物およびそれらの使用方法
AU2013305390C1 (en) 2012-08-24 2015-12-24 Ruyuan Wei Xiang Technology Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
KR20160077050A (ko) 2013-11-19 2016-07-01 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 화합물 및 이의 약제학적 용도
WO2015078391A1 (en) 2013-11-27 2015-06-04 Sunshine Lake Pharma Co., Ltd. Processes for preparing dihydropyrimidine derivatives and intermediates thereof
MX2016012573A (es) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
CN105859708B (zh) 2015-02-07 2020-01-21 广东东阳光药业有限公司 二氢嘧啶衍生物的盐及其在药物中的应用
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
EP3661929B1 (en) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0202654A3 (en) * 1985-05-20 1987-12-16 E.R. Squibb & Sons, Inc. 5-carboxy-1,4-dihydropyrimidine derivatives
EP0697407B1 (en) * 1994-08-19 1997-06-25 MITSUI TOATSU CHEMICALS, Inc. Pyrimidinedione derivatives and antiarrhythmic compositions containing same

Also Published As

Publication number Publication date
AU8249898A (en) 1999-01-25
WO1999001437A1 (en) 1999-01-14
SE9702563D0 (sv) 1997-07-02
US6057332A (en) 2000-05-02
EP0994859A1 (en) 2000-04-26
ZA985329B (en) 1999-01-11
CA2294882A1 (en) 1999-01-14
JP2002507988A (ja) 2002-03-12

Similar Documents

Publication Publication Date Title
AR013153A1 (es) Derivados de 2-arildihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados, y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n.
AR013152A1 (es) Derivados de 2-alquilheterodihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n.
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
HUP0003073A2 (hu) Benzolszulfonamid-származékok, eljárás előállításukra és gyógyszerként való alkalmazásuk
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
CY1107080T1 (el) Υποκατεστημενες ινδολο-βασεις του mannich
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
ECSP066667A (es) Derivados de ciclohexano espirociclicos
AR038045A1 (es) Agentes terapeuticos
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
UY28150A1 (es) Agentes terapeuticos
NO160516C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive, nye diazabicyclo-(3,3,1)-nonaner.
MX9207335A (es) Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene.
AR009938A1 (es) Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
AR037100A1 (es) Compuesto de pirimidina de anillo fusionado alquinilado, proceso de preparacion, compuestos intermedios, composicion farmaceutica y usi para preparacion de un producto medicinal
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR007088A1 (es) 2,4-diaminopirimidinas sustituidas, compuestos intermedios utilizados en su preparacion, procedimiento para la preparacion de dichas 2,4-diaminopirimidinas sustituidas, medicamentos que las contienen y empleos de dichas pirimidinas
AR016644A1 (es) Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos
ES2094742T3 (es) Aminocarbonilcarbamatos relacionados con fisostigmina, un procedimiento para su preparacion y su uso como medicamentos.
AR016551A1 (es) Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
MX9401080A (es) Compuestos heteroaromaticos.
DK1034174T3 (da) Azaringetherderivater og disses anvendelse som nikotin-ACh-receptormodulatorer
ES2102043T3 (es) Derivados de 22-en-25-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que los contienen, asi como su utilizacion en calidad de medicamentos.
ES2063117T3 (es) Derivados del tieno(2,3-d)acepina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.